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Mammalian birth is accompanied by a period of obligatory asphyxia, which consists
of hypoxia (drop in blood O2 levels) and hypercapnia (elevation of blood CO2
levels). Prolonged, complicated birth can extend the asphyxic period, leading to a
pathophysiological situation, and in humans, to the diagnosis of clinical birth asphyxia, the
main cause of hypoxic-ischemic encephalopathy (HIE). The neuroendocrine component
of birth asphyxia, in particular the increase in circulating levels of arginine vasopressin
(AVP), has been extensively studied in humans. Here we show for the first time that
normal rat birth is also accompanied by an AVP surge, and that the fetal AVP surge is
further enhanced in a model of birth asphyxia, based on exposing 6-day old rat pups
to a gas mixture containing 4% O2 and 20% CO2 for 45min. Instead of AVP, which is
highly unstable with a short plasma half-life, we measured the levels of copeptin, the
C-terminal part of prepro-AVP that is biochemically much more stable. In our animal
model, the bulk of AVP/copeptin release occurred at the beginning of asphyxia (mean
7.8 nM after 15min of asphyxia), but some release was still ongoing even 90min after the
end of the 45min experimental asphyxia (mean 1.2 nM). Notably, the highest copeptin
levels were measured after hypoxia alone (mean 14.1 nM at 45min), whereas copeptin
levels were low during hypercapnia alone (mean 2.7 nM at 45min), indicating that the
hypoxia component of asphyxia is responsible for the increase in AVP/copeptin release.
Alternating the O2 level between 5 and 9% (CO2 at 20%) with 5min intervals to mimic
intermittent asphyxia during prolonged labor resulted in a slower but quantitatively similar
rise in copeptin (peak of 8.3 nM at 30min). Finally, we demonstrate that our rat model
satisfies the standard acid-base criteria for birth asphyxia diagnosis, namely a drop in
blood pH below 7.0 and the formation of a negative base excess exceeding −11.2
mmol/l. The mechanistic insights from our work validate the use of the present rodent
model in preclinical work on birth asphyxia.
Keywords: arginine vasopressin (AVP), copeptin, birth asphyxia, hypothalamic-pituitary axis (HPA axis), blood
gases, base deficit, perinatal, neonatal
INTRODUCTION
In all mammalian species, the shift during parturition from maternal-fetal umbilical respiratory
gas exchange to the activation of fetal lungs is associated with a transient period of asphyxia in
the neonate. By definition, asphyxia implies a fall in blood O2 (hypoxia) that is associated with
an elevation of CO2 (hypercapnia). This period of obligatory, non-pathophysiological asphyxia is
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an essential part of the “stress of birth” (Van Woudenberg
et al., 2012; Evers and Wellman, 2016), which is beneficial
in that it activates the hypothalamic-pituitary axis (the HPA
axis) as well as the sympathetic nervous system. This, in turn,
triggers a wide range of cardiovascular and pulmonary responses
facilitating the adaptation of the newborn individual to extra-
uterine life (Lagercrantz and Slotkin, 1986; Van Woudenberg
et al., 2012; Lagercrantz, 2016). However, a prolonged period
of birth asphyxia is harmful, causing dysfunction and damage
with lifelong consequences in organ systems with a high and
predominantly aerobic energy metabolism, such as the brain
(Painter, 1995; Fattuoni et al., 2015; Ahearne et al., 2016).
In humans, various kinds of birth complications, such as
umbilical occlusion, prolonged labor, and delay in neonatal
lung function, can cause a pathophysiological state diagnosed
as clinical birth asphyxia, which is one of the leading causes
of neonatal death worldwide (Lawn et al., 2010; Lee et al.,
2013). While a lack of O2 has deleterious effects on a number
of organ systems, it is obvious that the neonatal human brain
is particularly sensitive to asphyxia-induced damage, known
as hypoxic-ischemic encephalopathy (HIE). Thus, survivors of
moderate to severe HIE show a high incidence of neurological
and psychiatric disorders later in life, including cerebral palsy,
mental retardation, mood disturbances, schizophrenia, and
epilepsy (Morales et al., 2011; Ahearne et al., 2016). In order
to understand the physiological mechanisms causing HIE, and
to develop therapies for the treatment of HIE, a wide variety of
animal models ranging from standard laboratory rodents to large
mammals such as piglets and sheep have been used to explore
the mechanisms, as well as short- and long-term consequences,
of birth asphyxia (Raff et al., 1991; Painter, 1995; Vannucci
and Vannucci, 1997; Johnston et al., 2005; Fattuoni et al., 2015;
Mallard and Vexler, 2015).
Most of the basic and clinical research on birth asphyxia
has focused on the hypoxia-induced defects in brain energy
metabolism (Tusor and Edwards, 2014), and on the consequences
thereof. However, the period of obligatory birth asphyxia related
to normal birth triggers massive neuroendocrine activation,
leading to an increase in the circulating levels of various
stress hormones such as arginine vasopressin (AVP) and
catecholamines (Chard et al., 1971; Lagercrantz and Slotkin,
1986; Wellmann et al., 2010). Even after normal vaginal
birth, the amount of AVP released into the circulation in the
human neonate reaches a level which is higher than under
any physiological or pathophysiological condition later in life
(Chard et al., 1971; Wellmann et al., 2010; Evers and Wellman,
2016). Notably, the surge in AVP secretion is further enhanced
by pathophysiological (clinical) birth asphyxia (Schlapbach
et al., 2011; Evers and Wellman, 2016; Summanen et al.,
2017).
AVP is mainly produced in the magnocellular neurons of
the paraventricular nucleus (PVN) and the supraoptic nucleus
(SON) of the hypothalamus, and released into the circulation
from the posterior pituitary (Koshimizu et al., 2012; Evers and
Wellman, 2016). AVP is highly unstable, with a plasma half-life of
only a couple of minutes, but the C-terminal part of preproAVP,
copeptin, that is released in an equimolar ratio to AVP, is
biochemically more stable, and has a plasma half-life of around
30min (Morgenthaler et al., 2006; L’Abate et al., 2013; Evers and
Wellman, 2016). The relatively long half-life of copeptin provides
a useful time-integrated signal of the net release of AVP. Thus,
copeptin is an ideal surrogate marker of peripheral AVP release
into the circulation.
Despite the relevance of AVP release for the diagnosis,
mechanisms, and therapies of birth asphyxia, and the prevalence
of rodent models of birth asphyxia, to our knowledge, there
are so far no studies investigating the role of AVP in birth
asphyxia in laboratory rodents (but see reference Spoljaric et al.,
2017). Here we show for the first time that normal birth
is accompanied by an AVP surge also in the rat, and that
in a novel rat model of birth asphyxia, where 6-day old rat
pups are exposed to a 45min period of steady or intermittent
asphyxia, AVP release as measured using copeptin can be
reliably evoked. Furthermore, we demonstrate that this model
satisfies the standard diagnostic criteria (Azzopardi et al., 2009;
Schlapbach et al., 2011; Summanen et al., 2017) of human birth
asphyxia based on blood pH and negative base excess (BE).
Our results provide important information on the kinetics of
AVP/copeptin release during asphyxia, and validate the use
of the current rodent model in preclinical work on birth
asphyxia.
MATERIALS AND METHODS
Animals
The experiments were performed on postnatal day (P) 0 female
or male, and P6 male Wistar rat pups. The P0 rats consisted
of two cohorts with one of them born normally, and the other
one taken just before birth by cesarean section at embryonic
day (E) 21.5 (see below). Both males and females were used at
P0 since we prioritized fast blood sample collection, and sexing
newborn animals would have delayed this process to a degree
that would have made the basic design and rationale of these
experiments meaningless. All procedures were approved by the
National Animal Ethics Committee of Finland and the local
animal ethics committee of the University of Helsinki.
Perinatal Blood Sampling
Rat embryo blood samples were collected at E21.5 from
timed-pregnant rat dams. The dams were anesthesized with
4.5% isoflurane, and anesthesia was maintained with 2.0–
2.3% isoflurane during cesarean section, after which the dam
was decapitated. After cesarean section, the embryos were
immediately decapitated and trunk blood was collected into
EDTA-coated tubes and placed on ice. Protease inhibitors
(Complete, Roche) were added and the samples were centrifuged
at 1,300 g, 4◦C for 10min. The plasma taken from all embryos
(9–15 pups/litter) in a given litter was combined into one sample
and stored at −80◦C until analysis. Blood samples collected at
birth were taken within 2min after normal delivery, and samples
from four pups from the same litter were combined into one
sample. Samples collected at 5–6 h postnatal were from individual
animals that experienced normal birth.
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Experimental Asphyxia and Blood Sample
Collection
All treatments were done in a closed experimental chamber at a
temperature of 33◦C (chamber volume∼1.5 L). The gas mixtures
(including room air) were humidified and pre-warmed, and
applied into the chamber at a constant flow rate of 1.5 L min−1.
Pups were put into the closed chamber 15min before applying a
gas mixture with compositions given below.
To study the time-dependent changes in copeptin levels
induced by experimental asphyxia, a gas mixture containing 4%
O2, 20% CO2 and 76% N2 (4% O2/20% CO2 asphyxia) was
applied for 5, 10, 15, or 45min. Trunk blood samples were
collected immediately after the treatment, or, alternatively, after
45min of asphyxia followed by exposure to room air for 30, 60, or
90min. Control animals were treated with room air, and samples
were collected at the same time points, except for 5 and 10min.
In order to compare the copeptin levels between the 4% O2/20%
CO2 asphyxia model described above, and the asphyxia model
used in our previous work (Helmy et al., 2011, 2012), male P6
rat pups were also exposed to 9% O2, 20% CO2, and 71% N2
(9% O2/20% CO2 asphyxia) for a period of 60min. Trunk blood
samples were collected at 15min of asphyxia, and at 30min post-
asphyxia. To check whether experimental asphyxia can evoke
AVP/copeptin release already at P0, pups were exposed to 15min
of 4% O2/20% CO2 asphyxia or room air (controls) 5–6 h after
birth, and trunk blood samples were collected.
A model of intermittent asphyxia was developed to more
accurately simulate prolonged, complicated labor. In this model,
male P6 rat pups were exposed to alternating, 5min periods of
9% O2/20% CO2 asphyxia and 5% O2/20% CO2 asphyxia (5%
O2, 20% CO2, and 75% N2), for a total of 45min. Trunk blood
samples were collected after 10, 20, 30, and 45min of asphyxia, as
well as after 45min of asphyxia followed by exposure to room air
for 30, 60, or 120min. Finally, the effects of hypoxia only (4% O2
in N2) and hypercapnia only (20% CO2, 20% O2, and 60% N2)
were studied by applying these gas mixtures to the rats for 15 and
45min.
Samples of trunk blood were collected into EDTA-coated
tubes and placed on ice. Protease inhibitors (complete, Roche)
were added, and the samples were centrifuged at 1,300 g, 4◦C
for 10min. The plasma was stored at −80◦C until analysis. To
avoid degradation of copeptin during storage, all samples were
analyzed on the ELISA/AlphaLISAwithin 2months after the date
of collection. Rats from at least two litters were used for each
experimental group at P6, and all samples were from individual
rat pups (thus, in contrast to the P0 animals, no combined
samples had to be used).
Blood Gas Analyses
Blood gas analyses were performed with a standard clinical GEM
Premier 4000 (Instrumentation Laboratory, Bedford, MA, USA)
blood gas analyzer. The blood was collected from the trunk of
the animal into a 80 µl heparin-coated capillary immediately
after decapitation, and analyzed within 5min after collection.
The “mixed venous” micro-protocol was used for the analysis
due to the sample type and obtainable volume. This protocol
has a pH cut-off of 6.8, and a pCO2 cut-off of 20 kPa, which
prevent the observation of lower and higher values, respectively.
Bicarbonate concentration ([HCO3]) was calculated according to
the following formula:
[HCO3] = pCO2 × 7.502× 10
pH−7.608
where numerical values of the partial pressure of CO2 (pCO2) are
substituted without their unit of kPa, and the obtained [HCO3]
values are in mM. The bicarbonate concentration was used to
calculate the base excess (BE, in mM):
BE = [HCO3]− 24.8+ 16.2×
(
pH− 7.4
)
In four out of five pups exposed to 4% O2/20% CO2 for 15min,
the pH was below 6.8 (in one pup the pH was 6.85), and in all
five pups the pCO2 was above 20 kPa. With these cut-off values
of pH and pCO2 the above equations yield a BE of −11.2mM,
which, however, is not a cut-off value for BE (a lower value was
calculated for one pup exposed to hypoxia; see Figure 5C).
Copeptin ELISA
Copeptin concentrations in rat plasma were measured using
a sandwich ELISA (Summanen et al., 2017). Nunc Maxisorp
plates (Thermo Scientific) were coated with 1 µg of sheep anti-
copeptin (gift from Thermo Fisher Scientific) per well in 100 µl
of PBS overnight at 4◦C. The next day, wells were blocked
for 1 h RT shaking with 200 µl of 4% skimmed milk in PBS
(PBS-M) per well. A serial dilution (0–40 ng/ml) of rat copeptin
(Bachem) was made in 2% PBS-M and used as a standard
on every ELISA plate. Rat plasma samples were diluted 2.5
times in 2% PBS-M and 100 µl of standards and samples were
pipetted to the plate in duplicate and incubated with shaking
for 2 h at RT. Next, wells were washed 3 times with 200 µl of
PBS per well and bound copeptin was detected with a 1:1,000
dilution of goat anti-copeptin (Santa Cruz Biotechnology) in
2% PBS-M (1 h at RT shaking, 100 µl/well). After washing
the plate 6 times with PBS, the plate was incubated for 1 h
at RT shaking with a 1:5,000 dilution of mouse anti-goat
horse radish peroxidase (HRP)-conjugated secondary antibody
(Abcam) in 2% PBS-M. Antibody binding was visualized with
o-phenylenediamine dihydrochloride (OPD; SigmaFast tablets,
Sigma) and the plate was scanned at 450 nm with a plate reader
(Biorad) 30min after OPD addition.
Copeptin AlphaLISA
To improve the sensitivity of the copeptin assays, an alternative
method using the same copeptin antibodies was developed
based on AlphaLISA technology (PerkinElmer). The goat anti-
copeptin antibody (SantaCruz Biotechnology) was conjugated
to AlphaLISA acceptor beads according to the manufacturer’s
instructions. The sheep anti-copeptin antibody was biotinylated
with EZ-LinkTM Sulfo-NHS-SS-Biotin (Thermo Scientific). A
serial dilution of rat copeptin (0–160 ng/ml) in adult rat plasma
devoid of copeptin was used as a standard.
The assay was performed in triplicate in 384-well Alpha plates.
First, 5 µl of blank plasma, standard or sample was pipetted to
the plate, and 10 µl of goat anti-copeptin conjugated AlphaLISA
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acceptor beads at a final concentration of 20µg/ml were added
to each well. After 1 h incubation, 10 µl of biotinylated sheep
anti-copeptin at a final concentration of 5 nM was added to
each well, and the plate was incubated for 1 h. Finally, 25 µl
of AlphaLISA Streptavidin donor beads at a final concentration
of 40µg/ml was added to each well, and after incubating for
1 h, the plate was read with an EnSpire multimode plate reader
(PerkinElmer). The resulting AlphaLISA signal was analyzed
using a 4-parameter logistic regression curve fit on GraphPad
Prism. The lowest detection limit (LDL), calculated as 3 times the
standard deviation of the blank mean, was 0.2 nM. The average
coefficient of variation (CV) from the three replicates per sample
was 3.5%. The ELISA and AlphaLISA methods gave identical
results for samples collected in the same way (see Supplementary
Figure 1).
Statistical Analysis
Data are given as mean ± SEM. The statistical analyses were
performed with GraphPad Prism 6. The copeptin concentrations
between treatment groups were compared using the Mann–
Whitney U-test or the Kruskal–Wallis test. The blood gas
parameters between groups were compared with the Kruskal–
Wallis test.
RESULTS
Increase in Serum Copeptin at Birth in the
Rat
Several studies have shown that AVP/copeptin levels are
increased after normal vaginal birth in human neonates (Chard
et al., 1971; Wellmann et al., 2010), whereas neonates born by
elective cesarean section generally have very low serum copeptin
levels (Wellmann et al., 2010). Rather surprisingly, we have not
been able to find any literature on the likely birth-induced AVP
response in standard laboratory rodents. Therefore, we collected
trunk blood samples from rat pups after cesarean section just
before birth (E21.5), within 2min after birth [P0(2min)], and
5 h after birth [P0(5 h)]. The copeptin levels showed a significant
increase in the P0(2min) pups (mean 1.8 ± 0.1 nM), and had
returned to baseline levels 5 h after birth (Figure 1A). These data
indicate that normal birth increases peripheral AVP/copeptin
release in rats as well as in humans, pointing to the presence
of the evolutionary highly conserved birth-associated protective
endocrine response also in laboratory rodents (see section
Introduction). This conclusion gained further support from the
fact that a 15min period of experimental asphyxia induced a
pronounced increase in plasma copeptin in all P0(5 h) rat pups
tested (Figure 1B).
Experimental Asphyxia Increases
Peripheral Copeptin Levels
The time-dependent changes in copeptin levels were studied
by exposing P6 rat pups to 4% O2/20% CO2 asphyxia for a
period of 45min. The peak in mean copeptin concentration (7.8
± 1.3 nM) was observed at 15min after the start of asphyxia
(Figure 2A), and by the end of asphyxia at 45min, the mean
copeptin level had decreased to 5.1 ± 1.0 nM, followed by
a further decrease to 1.4 ± 0.2 nM at 30min post-asphyxia.
After that, the copeptin levels stayed relatively stable beyond
90min post-asphyxia, indicating that a significant amount of
copeptin release was still ongoing during the recovery period.
In control animals breathing room air, copeptin concentrations
remained close to 0 nM at all time points studied (Figure 2A).
Thus, experimental asphyxia leads to enhanced AVP/copeptin
secretion in rat pups in the 4% O2/20% CO2 asphyxia
model.
In our previous work (Helmy et al., 2011, 2012) we
have used an experimental paradigm where P6 rat pups
were exposed to 9% O2/20% CO2 asphyxia for a period of
60min. Therefore, we compared asphyxia induced copeptin
release using the two O2 levels and application times. After
15min of asphyxia the mean copeptin concentration was
FIGURE 1 | Normal birth (A) and experimental asphyxia (B) increase copeptin levels in P0 rat pups. (A) E21.5 samples were collected after cesarean section of the
dam, and blood samples taken from all pups in a given litter were pooled into one sample for analysis. The P0(2min) samples were collected within 2min after normal
birth, and blood from 4 pups from the same litter was pooled for each sample. P0(5 h) samples were collected 5–6 h after normal birth, and blood from each pup was
analyzed separately. (B) Copeptin levels in P0 pups exposed to 4% O2/20% CO2 asphyxia for 15min, and in controls breathing room air. Blood from each pup was
analyzed separately. The mean ± SEM is shown for each time point, p-values from the Kruskal–Wallis test (A) or Mann–Whitney U-test (B) are shown when the
difference was statistically significant.
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FIGURE 2 | Copeptin concentrations in the P6 rat model of birth asphyxia. (A) Plasma copeptin levels in male P6 rats undergoing asphyxia and in controls breathing
room air. Maximum plasma copeptin levels were observed after 15min of asphyxia, after which copeptin levels steadily decreased until a plateau was reached at
30min post-asphyxia. For asphyxia, n = 3 at 5min of asphyxia, and 5–8 at all other time points. For controls, n = 3–4 at all time points. (B) Plasma copeptin levels
were lower when rats were exposed to 9% O2/20% CO2 asphyxia compared to 4% O2/20% CO2 asphyxia. For 4% O2/20% CO2 asphyxia, n = 5 at 15min and 7 at
45+30min. For 9% O2/20% CO2 asphyxia, n = 3 at both time points. Copeptin concentrations were measured with the ELISA, and the data are shown as mean ±
SEM. In (B) p-values from Mann–Whitney U-tests are shown when the difference was statistically significant.
significantly lower in rat pups exposed to 9% O2/20% CO2
compared to 4% O2/20% CO2 (2.2 vs. 7.8 nM; Figure 2B).
This was still the case at 30min post-asphyxia (1.1 vs.
1.4 nM), but the difference was no longer statistically
significant.
Copeptin Levels after Intermittent Asphyxia
During prolonged, complicated labor the oxygen levels
experienced by the fetus are not steady, but fluctuate for example
due to uterine contractions. In order to simulate this aspect of
birth more accurately, we developed a model of intermittent
asphyxia, where the oxygen level alternated between 9 and 5%
every 5min with the CO2 level kept at 20%. In this model,
the highest copeptin concentrations were observed at 30min
after the start of asphyxia (8.3 ± 0.9 nM; Figure 3), followed
by a decrease to 5.2 ± 0.8 nM at the end of asphyxia at 45min.
Thirty minutes after the end of asphyxia the mean copeptin
concentration was 2.4 ± 0.2 nM. Thereafter, copeptin levels
stayed elevated at around 2 nM beyond 120min post-asphyxia
(Figure 3).
What Is the Trigger for Copeptin Release,
Hypoxia or Hypercapnia?
The effects of hypoxia and hypercapnia, the two components of
asphyxia, on copeptin release were studied separately by exposing
the rat pups to either hypoxic or hypercapnic conditions for
a period of 45min. Hypoxia induced the highest increase in
copeptin concentrations (Figure 4), with means of 10.3 and
14.1 nM at 15 and 45min, respectively (compared to 7.8 and
5.1 nM for asphyxia, and 1.2 and 2.7 nM for hypercapnia).
Decrease in pH and Increase in Negative
Base Excess during Experimental Asphyxia
To examine whether the 4% O2/20% CO2 asphyxia model
reproduces the standard diagnostic characteristics of birth
asphyxia (Azzopardi et al., 2009; Schlapbach et al., 2011;
FIGURE 3 | Copeptin concentrations during and after intermittent asphyxia.
Maximum plasma copeptin concentrations were observed at 30min following
the onset of intermittent asphyxia, after which copeptin levels steadily
decreased. n = 4–6 samples for all time points. Copeptin concentrations were
measured with the AlphaLISA, and the mean ± SEM is shown for each time
point.
Summanen et al., 2017), we measured the blood gas values
in asphyxiated and control pups (Figure 5). After 15min of
asphyxia, the blood pH fell to levels of 6.8 or lower, and BE was
below −11.2mM. The pH and BE were significantly lower in
asphyxiated compared to control pups, whereas the pCO2 levels
were significantly higher in the asphyxiated animals compared
to controls. Thus, our P6 model does not only reproduce the
AVP/copeptin response to asphyxia, but it also demonstrates the
presence of a significant negative BE.
Interestingly, a 15min period of hypoxia did not alter the
blood pH compared to control animals (Figure 5A). Moreover,
the pCO2 levels were lower than in the controls, leading to the
generation of a negative BE (mean −5.7mM, Figure 5B). In
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contrast, 15min of hypercapnia caused a decrease in blood pH,
and an increase in pCO2 levels compared to control animals, but
the BE remained positive (Figure 5).
DISCUSSION
AVP is an evolutionarily ancient signaling factor, which targets
the V1a, V1b, and V2 receptors (Koshimizu et al., 2012) in
various organ systems, including those that are known to be
prone to the hypoxic challenge (in particular, the brain, kidneys,
and liver) that takes place during both normal and complicated
birth (Spoljaric et al., 2017). The fetal AVP surge occurring during
normal vaginal birth was first described almost 50 years ago
FIGURE 4 | Copeptin blood levels in male P6 rats during 45min exposures to
4% O2/20% CO2 asphyxia, 4% O2/0% CO2 hypoxia, and 20% O2/20% CO2
hypercapnia. The highest copeptin levels were observed after 45min of
hypoxia. n = 4–6 for all conditions, except for n = 3 for controls at 45min.
Copeptin concentrations were measured with the ELISA, and the mean ±
SEM is shown for each condition. p-values from Kruskall–Wallis tests are
shown where the difference was statistically significant.
(Chard et al., 1971), and reports of the catecholamine surge
followed a few years later (Lagercrantz and Bistoletti, 1977).
AVP is derived from a larger precursor peptide, prepro-AVP,
along with neurophysin II and the C-terminal 39-amino acid
glycopeptide copeptin (de Bree and Burbach, 1998). During
the last 10 years, copeptin has been used as an advantageous
surrogate marker for AVP release (see section Introduction and
references Morgenthaler et al., 2006, 2008). Several studies have
reported an increase in serum copeptin levels following normal
vaginal birth (Wellmann et al., 2010; Summanen et al., 2017),
and, notably, the increase in copeptin levels is further accentuated
by neonatal stress, such as birth asphyxia (Schlapbach et al., 2011;
Summanen et al., 2017).
Here, we show for the first time that normal birth causes an
increase in circulating levels of AVP/copeptin also in the rat.
In plasma samples collected within 2min after normal birth the
mean copeptin concentration was 1.8 nM, compared to amean of
0.9 nM in samples collected after cesarean section of the dam. The
copeptin levels had decreased to baseline levels within 5–6 h after
birth (Figure 1A). The cesarean section samples were collected at
E21.5, which means that in some of the dams labor had probably
started. This is likely why the copeptin concentrations in these
samples are higher than those reported for human neonates
after elective cesarean section. A 15min period of experimental
asphyxia was able to induce a second AVP/copeptin surge 5–6 h
after normal birth (Figure 1B).
Moreover, we show that a rat model of birth asphyxia
replicates the clinical findings of increased AVP/copeptin release
in asphyxiated neonates. Sampling at several time-points allowed
us to study the time-dependent changes in copeptin release
during and after the asphyxic period. When pups were exposed
to 4% O2/20% CO2 asphyxia for 45min, plasma copeptin levels
peaked already after 15min of asphyxia (mean 7.8 nM), after
which the levels steadily decreased. Considering the around
30min half-life of copeptin in plasma (L’Abate et al., 2013),
FIGURE 5 | Changes in pH (A), pCO2 (B), and base excess (C) after 15min of 4% O2/20% CO2 asphyxia, 4% O2/0% CO2 hypoxia, and 20% O2/20% CO2
hypercapnia. See section Materials and Methods for an explanation of the cut-off values in the 4% O2/20% CO2 asphyxia group. Means ± SEM are shown. p-values
from Kruskall–Wallis tests are shown where the difference was statistically significant.
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it is clear that the bulk of copeptin release in this model
occurs at the very beginning of asphyxia, but that some release
is still ongoing even 90min after the end of asphyxia. In
the clinic, the first sample available for biomarker analysis is
from the umbilical cord, but the asphyxic period could have
occurred at any point during labor. Therefore, based on these
results, it is reasonable to assume that the AVP/copeptin levels
in the neonate are even higher in utero than the extremely
high values measured from umbilical cord blood. In fact, in
our previous study we reported copeptin values of 2.3 nM in
umbilical cord samples of human neonates diagnosed with
birth asphyxia (Summanen et al., 2017), which is in the same
order of magnitude as the 5.1 nM reported here for the end of
asphyxia.
Notably, our present data show that the copeptin levels did
not fall to the control value during the recovery period but
remained at an elevated level, which indicates that sustained
peripheral AVP release takes place for a lengthy period of
time after the asphyxia. Thus, the various actions of AVP,
including the adaptive ones described in the Introduction, do
not end abruptly after the asphyxic insult. Moreover, it is
important to note that the post-asphyxia levels of copeptin
seen in the present model are analogous to those measured
in neonatal blood samples after birth (Kelen et al., 2017). In
our previous work on copeptin as a diagnostic and prognostic
biomarker of HIE, the median copeptin concentration 1 week
after birth in infants diagnosed with HIE was 17.8 pmol/l
(Kelen et al., 2017), which is still above the normal range for
healthy volunteers (Struck et al., 2005; Morgenthaler et al.,
2006).
In human neonates, uterine contractions, which are
accompanied by transient episodes of fetal hypoxia, are
known to increase fetal copeptin levels as recently shown using
an oxytocin-challenge test before elective cesarean section
(Wellmann et al., 2016). Furthermore, copeptin levels strongly
correlate with labor duration, and hence an increased number of
contractions, and in particular the duration of the second stage of
labor (Summanen et al., 2017). Therefore, we developed another
paradigm (intermittent asphyxia), where rat pups were exposed
to alternating 5min periods of 9% O2/20% CO2 asphyxia and
5% O2/20% CO2 asphyxia. The pulses of more severe asphyxia
combined with milder asphyxia were designed to mimic uterine
contractions. In intermittent asphyxia copeptin levels peaked at
30min of asphyxia (vs. 15min as measured in the 4% O2/20%
CO2 asphyxia model), and the concentrations remained elevated
at∼2 nM beyond 120min post-asphyxia.
Interestingly, the highest copeptin concentrations (mean
14.1 nM) were measured after 45min of hypoxia. Hypercapnia
alone resulted in much lower copeptin release compared to
asphyxia. Therefore, it is the hypoxia component of asphyxia
that is responsible for the increased AVP/copeptin release
observed during asphyxia. This is in agreement with previous
results from adult rats, where acute hypoxia resulted in
significantly increased copeptin release (L’Abate et al., 2013;
Ostergaard et al., 2014). Furthermore, it has been shown
that acute hypoxia activates AVP-neurons in the PVN (King
et al., 2012; Coldren et al., 2017). Importantly, there was
no increase in copeptin concentrations in any of the control
animals breathing room air. Therefore, the stress from the
experimental paradigm, including maternal separation, was not
sufficient to induce copeptin release in the 6-day old rat
pups.
The standard diagnostic criteria for birth asphyxia usually
include a fall in blood pH and a negative base excess. Typically,
the criterion level of acidotic blood pH for birth asphyxia
diagnosis is set between 7.0 and 7.1, with an additional and
highly important criterion of a BE level in the range of −12
to −16mmol/l (Azzopardi et al., 2009; Schlapbach et al., 2011;
Kelen et al., 2017; Summanen et al., 2017). In our 4% O2/20%
CO2 asphyxia model, the blood pH was <6.8 after 15min of
asphyxia, and the BE was <−11.2mmol/l (see section Materials
and Methods for an explanation of the cut-off values). Therefore,
in addition to mimicking the neuroendocrine response of clinical
birth asphyxia, our model also satisfies the standard acid-base
diagnostic criteria of birth asphyxia. In our previous work we
have used a model where 6-day old rat pups were exposed to
9% O2/20% CO2 asphyxia for 60min (Helmy et al., 2011, 2012).
However, in the 9% O2/20% CO2 asphyxia model the blood pH
at the end of asphyxia was 7.25 (Helmy et al., 2011), which was
significantly lower compared to controls but above the threshold
for birth asphyxia diagnosis. This, coupled with the fact that
copeptin release was significantly lower during 9% O2/20% CO2
asphyxia compared to 4% O2/20% CO2 asphyxia, indicates that
an oxygen level of 9% is not sufficient to model clinical birth
asphyxia in the 6-day old rat pup.
Animal models have been extensively used in studies of
birth asphyxia (see section Introduction; and references Painter,
1995; Vannucci and Vannucci, 1997; Johnston et al., 2005;
Mallard and Vexler, 2015) but, as far as we know, our present
study is the first one to show that, in a clinically relevant
rodent model of birth asphyxia as indicated by the relevant
blood parameters, a massive surge of AVP takes place. This
kind of a mechanism is likely to play an important role in
“developmental plasticity” of an individual, thereby contributing
to the allostatic, preadaptive mechanisms (McEwen, 1998) that
help the individual to adjust to the process of birth itself,
and also to the postnatal conditions experienced afterwards
(Hanson and Gluckman, 2014). To conclude, the data presented
here provide important mechanistic insights on the kinetics of
AVP/copeptin release triggered by asphyxia: namely that most
of the release occurs at the beginning of asphyxia; and the
release continues after the asphyxia ends, which is in agreement
with results from human neonates (Kelen et al., 2017). Notably,
the data on both copeptin release and blood-gas parameters
validate the current rodent model for preclinical work on birth
asphyxia.
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